Grace Medical, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$556Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
117clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Levine Irrigation Suction Tubing $73K associated (2023-2025)
- Kraus K-Helix Implants $26K associated (2023-2025)
- Bojrab Alto and Piston Implants $14K associated (2023-2025)
- Rivas Surgical Instruments $13K associated (2023-2025)
- 2 In 1 Alto Implant $3,674 associated (2023-2025)
- Bartels Bucket Implants $2,053 associated (2023-2025)
- 2 In 1alto Implant $1,795 associated (2023-2025)
- Titanium/Otosil Implants $48.32 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Samuel Levine | Minneapolis, MN | Otolaryngology | $142,995.96 |
| James Freeman | Memphis, TN | Ophthalmology | $127,500.00 |
| John Freeman | Memphis, TN | Ophthalmology | $127,500.00 |
| Eric Kraus | Winston Salem, NC | Otology & Neurotology | $52,506.66 |
| Dennis Bojrab | Farmington Hills, MI | Otology & Neurotology | $24,757.81 |
| Alejandro Rivas Campo | Cleveland, OH | Otology & Neurotology | $23,025.54 |
| Loren Bartels | Tampa, FL | Otology & Neurotology | $15,964.27 |
| Douglas Backous | Puyallup, WA | Otolaryngology | $7,758.98 |
| Dennis Bojrab | Farmington Hills, MI | Otology & Neurotology | $3,486.33 |
| John Dornhoffer | Little Rock, AR | Otology & Neurotology | $1,868.72 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.